Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04430738 |
Title | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers |
Recruitment | Recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Seagen Inc. |
Indications | |
Therapies |
Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib |
Age Groups: | adult | senior |
Covered Countries | USA |